Suppr超能文献

肝硬化患者合并细菌感染时肝脏储备功能不良的影响:一项基于人群的研究。

Effects of poor hepatic reserve in cirrhotic patients with bacterial infections: A population-based study.

作者信息

Hung Tsung-Hsing, Tsai Chih-Chun, Lee Hsing-Feng

机构信息

Division of Gastroenterology, Department of Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.

School of Medicine, Tzu Chi University, Hualien, Taiwan.

出版信息

Tzu Chi Med J. 2019 Feb 18;32(1):47-52. doi: 10.4103/tcmj.tcmj_142_18. eCollection 2020 Jan-Mar.

Abstract

OBJECTIVE

Ascites, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, and esophageal variceal bleeding are major complications associated with cirrhosis. The presence of these complications indicates poor hepatic reserve. This study aimed to identify the effects of poor hepatic reserve on mortality in cirrhotic patients with bacterial infections.

PATIENTS AND METHODS

The Taiwan National Health Insurance Database was used to identify 43,042 cirrhotic patients with bacterial infections hospitalized between January 1, 2010, and December 31, 2013, after propensity score matching analysis. Of these, 21,521 cirrhotic patients had major cirrhotic-related complications and were considered to have poor hepatic reserve.

RESULTS

Mortality rates at 30 and 90 days were 24.2% and 39.5% in the poor hepatic reserve group and 12.8% and 21.7% in the good hepatic reserve group, respectively ( < 0.001 for each group). The cirrhotic patients with poor hepatic reserve (hazard ratio [HR], 2.10; 95% confidence interval [CI] = 2.03-2.18; < 0.001) had significantly increased mortality at 90 days. The mortality HRs in patients with one, two, and three or more complications compared to patients without complications were 1.92 (95% CI = 1.85-1.99, < 0.001), 2.61 (95% CI = 2.47-2.77, < 0.001), and 3.81 (95% CI = 3.18-4.57, < 0.001), respectively.

CONCLUSION

In cirrhotic patients with bacterial infections, poor hepatic reserve is associated with a poor prognosis. The presence of three or more cirrhotic-related complications increases mortality almost four folds.

摘要

目的

腹水、肝性脑病、肝肾综合征、自发性细菌性腹膜炎和食管静脉曲张破裂出血是肝硬化相关的主要并发症。这些并发症的出现表明肝脏储备功能差。本研究旨在确定肝脏储备功能差对肝硬化合并细菌感染患者死亡率的影响。

患者与方法

在进行倾向得分匹配分析后,利用台湾国民健康保险数据库确定了2010年1月1日至2013年12月31日期间住院的43042例肝硬化合并细菌感染患者。其中,21521例肝硬化患者出现了主要的肝硬化相关并发症,被认为肝脏储备功能差。

结果

肝脏储备功能差的患者30天和90天死亡率分别为24.2%和39.5%,肝脏储备功能良好的患者分别为12.8%和21.7%(每组均<0.001)。肝脏储备功能差的肝硬化患者90天死亡率显著增加(风险比[HR],2.10;95%置信区间[CI]=2.03-2.18;<0.001)。与无并发症的患者相比,有1种、2种和3种及以上并发症的患者的死亡HR分别为1.92(95%CI=1.85-1.99,<0.001)、2.61(95%CI=2.47-2.77,<0.001)和3.81(95%CI=3.18-4.57,<0.001)。

结论

在肝硬化合并细菌感染的患者中,肝脏储备功能差与预后不良相关。出现3种及以上肝硬化相关并发症会使死亡率增加近4倍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d85d/7015002/ec3dd9abd56d/TCMJ-32-47-g001.jpg

相似文献

1
Effects of poor hepatic reserve in cirrhotic patients with bacterial infections: A population-based study.
Tzu Chi Med J. 2019 Feb 18;32(1):47-52. doi: 10.4103/tcmj.tcmj_142_18. eCollection 2020 Jan-Mar.
4
High Mortality of Cirrhotic Patients With End-Stage Renal Disease.
Medicine (Baltimore). 2016 Mar;95(10):e3057. doi: 10.1097/MD.0000000000003057.
5
Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
Clin Gastroenterol Hepatol. 2022 Jun;20(6):1382-1393.e19. doi: 10.1016/j.cgh.2021.07.010. Epub 2021 Jul 10.
7
The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy.
Epidemiol Infect. 2013 Dec;141(12):2671-8. doi: 10.1017/S0950268813000186. Epub 2013 Feb 22.
9
Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy.
Therap Adv Gastroenterol. 2024 May 27;17:17562848241254267. doi: 10.1177/17562848241254267. eCollection 2024.

本文引用的文献

1
Selective cyclooxygenase inhibition by SC-560 improves hepatopulmonary syndrome in cirrhotic rats.
PLoS One. 2017 Jun 20;12(6):e0179809. doi: 10.1371/journal.pone.0179809. eCollection 2017.
3
Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study.
Am J Gastroenterol. 2016 Jul;111(7):976-85. doi: 10.1038/ajg.2016.179. Epub 2016 May 10.
4
The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites.
Am J Med Sci. 2016 Feb;351(2):169-76. doi: 10.1016/j.amjms.2015.11.018.
5
Can proton pump inhibitors reduce rebleeding following Histoacryl sclerotherapy for gastric variceal hemorrhage?
Korean J Intern Med. 2015 Sep;30(5):593-601. doi: 10.3904/kjim.2015.30.5.593. Epub 2015 Aug 27.
6
Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance.
J Hepatol. 2014 Dec;61(6):1385-96. doi: 10.1016/j.jhep.2014.08.010. Epub 2014 Aug 15.
7
Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation.
Clin Res Hepatol Gastroenterol. 2014 Oct;38(5):570-6. doi: 10.1016/j.clinre.2014.07.004. Epub 2014 Aug 15.
9
Immune dysfunction in cirrhosis.
World J Gastroenterol. 2014 Mar 14;20(10):2564-77. doi: 10.3748/wjg.v20.i10.2564.
10
High mortality of pneumonia in cirrhotic patients with ascites.
BMC Gastroenterol. 2013 Feb 7;13:25. doi: 10.1186/1471-230X-13-25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验